Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | NOS1 | P29475 | 3/20 | 0.38 |
| ▸ | NOS3 | P29474 | 2/20 | 0.38 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GSR | P00390 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | TTK | P33981 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15872023 | 0.89 | ALDH1A1 (0.46) | ALDH1A1TSHRNOS1NOS3NOS2 | |
| SCHEMBL4643735 | 0.86 | ALDH1A1 (0.50) | ALDH1A1TSHRNOS1NOS3NOS2 | |
| SCHEMBL14075736 | 0.84 | ALDH1A1 (0.46) | ALDH1A1TSHRNOS1NOS3NOS2 | |
| SCHEMBL4526629 | 0.82 | ALDH1A1 (0.46) | ALDH1A1TSHR | |
| SCHEMBL15077303 | 0.79 | ALDH1A1 (0.48) | ALDH1A1TSHRNOS1NOS3NOS2 | |
| SCHEMBL1098664 | 0.77 | ALDH1A1 (0.41) | ALDH1A1TSHRLMNAHRH3SLC6A4 | |
| SCHEMBL20837049 | 0.77 | HRH3 (0.40) | ALDH1A1TSHRNOS1NOS3NOS2 | |
| SCHEMBL14088678 | 0.77 | ALDH1A1 (0.63) | ALDH1A1TSHRNOS1NOS3NOS2 | |
| SCHEMBL427399 | 0.76 | NOS1 (0.51) | ALDH1A1TSHRNOS1NOS3NOS2 | |
| SCHEMBL27389057 | 0.75 | ALDH1A1 (0.43) | ALDH1A1TSHRLMNAGAATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973164-B2 | Quinoline derivatives | ASTRAZENECA AB (SE) | 2011-07-05 | — | — | US | disclosed |
| US-20090233950-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| CN-101437811-A | Quinoline derivatives | ASTRAZENECA AB (SE) | 2009-05-20 | — | — | CN | disclosed |
| CN-101437810-A | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-05-20 | — | — | CN | disclosed |
| CN-101437812-A | Quinoline derivatives for the treatment of cancer | ASTRAZENECA AB (SE) | 2009-05-20 | — | — | CN | disclosed |
| CN-101432276-A | Quinoline derivatives | ASTRAZENECA AB (SE) | 2009-05-13 | — | — | CN | disclosed |
| US-20090076075-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076074-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20090042910-A1 | QUINOLINE DERIVATIVES FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | disclosed |
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | PLE PATRICK | 2009-02-05 | — | — | US | disclosed |
| EP-1994024-A2 | QUINOLINE DERIVATIVES | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| EP-1994023-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| EP-1994028-A1 | QUINOLINE DERIVATIVES FOR TREATING CANCER | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007113565-A1 | NAPHTHYRIDINE DERIVATIVES AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007099323-A2 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007099335-A1 | QUINOLINE DERIVATIVES FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007099317-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007099326-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | disclosed |
| EP-1802608-A1 | QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040526-A1 | QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076075-A1 | QUINOLINE DERIVATIVES | RECQL, NQO2, NRAS | ALDH1A1 832/4885TSHR 978/4885NOS1 1050/4885 |
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | AQP3, AQP1, F12 | ALDH1A1 2449/4885TSHR 2524/4885NOS1 407/4885 |
| US-20090042910-A1 | QUINOLINE DERIVATIVES FOR TREATING CANCER | RECQL, NQO2, NRAS | ALDH1A1 932/4885TSHR 1590/4885NOS1 999/4885 |
| US-20090233950-A1 | QUINAZOLINE DERIVATIVES | NQO2, CCNI, F12 | ALDH1A1 1940/4885TSHR 1084/4885NOS1 1319/4885 |
| US-20090076074-A1 | QUINOLINE DERIVATIVES | RECQL, NQO2, CCNA1 | ALDH1A1 887/4885TSHR 1179/4885NOS1 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.